CRPC w/ Bone Metastases VL

Quantified Bone Scan Response After Radium-223

Details
ASCO 2014 - A Randomized, Open-Label Phase 2a Study Evaluating Quantified Bone Scan Response Following Treatment with Radium-223 Dichloride Alone or in Combination with Abiraterone Acetate or Enzalutamide in Patients with Castration-Resistant Prostate Cancer who have Bone Metastases Daniel Petrylak, MD discusses a study designed to explore the utility of bone scan imaging to assess treatment respo...

Bone-targeted Therapies and Radiopharmaceuticals

Details
Bone-targeted Therapies and Radiopharmaceuticals Daniel Petrylak, MD discusses alpha-emitting isotope therapy and hormonal chemotherapeutic agents and the survival rate of men with CRPC. Daniel Petrylak, MD Yale Cancer Center

Height-Based Dosing with Ra-223

Details
Consideration of Height-based Rather than Weight-based Dosing as a More Appropriate Method of Treating with Ra-223 Thomas Longo, MD discusses a study designed to explore the safety profile of radium-223 in the context of height-based dosing regimen. Thomas A. Longo, MD Click HERE to view the poster from this session

Radium-223 in mCRPC

Details
Radium-223 Chloride (Alpharadin) in Patients with Bone Metastases and Castration-resistant Prostate Cancer (CRPC): A New Treatment Paradigm Professor Sartor discusses a study of CRPC patients with bone metastases which showed that radium-223 significantly prolonged overall survival and time to first skeletal-related event, and was well tolerated. A. Oliver Sartor, MD Laborde Professor of Cancer Re...